Colleen Veloski, MD, FACE, ECNU
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Associate Professor Temple University School of Medicine, Philadelphia, PA
Dr. Veloski, FACE, ECNU's
(Feb 11, 2013)
Evaluation and treatment of thyroid nodules and thyroid cancer, thyroid ultrasound and ultrasound guided fine needle aspiration biopsy, thyroid hormone replacement therapy following thyroid cancer treatment, parathyroid tumors, parathyroid disorders, tumors and disorders of the adrenal gland, MEN1, MEN2.
American Board of Internal Medicine Diplomate in Internal Medicine;:
American Board of Internal Medicine Diplomate in Endocrine, Diabetes and Metabolism;
American Association of Clinical Endocrinologists, Endocrine Certification in Neck Ultrasound (ECNU)
As an endocrinologist specializing in thyroid and parathyroid disorders, and malignancy related endocrine problems, my expertise meets the needs of a broad range of patients who seek or have received treatment at Fox Chase Cancer Center.
Early in my career, I developed an interest in the diagnosis and management of thyroid cancer. While thyroid nodules are very common, only 5-10% of all thyroid nodules are malignant. Fine needle aspiration biopsy can differentiate malignant nodules from benign nodule with a high degree of accuracy, but it is not possible or advisable to biopsy the thousands of benign thyroid nodules discovered each year. In the last 5-10 years, research in the area of thyroid nodules and thyroid cancer has shown that ultrasonographic characteristics combined with other risk stratification factors can direct us to biopsy only those nodules with a higher risk of clinically significant malignancy. This results in fewer diagnostic procedures and unnecessary surgeries. As a result, I have developed my skills in the areas of thyroid ultrasound and ultrasound guided fine needle aspiration biopsy in order to comprehensively manage and follow thyroid nodules. I am certified in neck ultrasound by the American Association of Clinical Endocrinologists.
Patients who are ultimately diagnosed with thyroid cancer will be managed by our multidisciplinary treatment team. Most of these patients require surgery, and perhaps, radioiodine treatment, that result in lifelong hypothyroidism. As a specialized endocrinologist, I can manage the initial cancer treatment, ongoing monitoring for thyroid cancer recurrence, and thyroid hormone replacement therapy for thyroid cancer patients. I also treat patients who develop hypoparathyroidism that can rarely occur following any head or neck surgery. We also evaluate and treat patients with hyperparathyroidism due to parathyroid tumors.
I work with other Fox Chase Cancer Center surgeons and oncologists to manage patients with other endocrine related tumors such as adrenal, pituitary, and neuroendocrine tumors. We monitor and treat patients with genetic tumor syndromes affecting the endocrine organs such as the multiple endocrine neoplasia syndromes, MEN1 and MEN2. When patients with other malignancies develop endocrine problems related to their cancer treatment, they can receive evaluation and treatment at Fox Chase allowing for better coordination of care. I believe that patients receive the best care when all of the caregivers communicate among each other and, most importantly, to the patients. At Fox Chase, our thyroid cancer team includes specialists from endocrinology, medical oncology, surgical oncology, radiation oncology, radiology, pathology, and nuclear medicine. Patients with other endocrine malignancies or endocrine problems related to malignancy are also managed by a multidisciplinary team. Together along with our dedicated, experienced, compassionate support staff, we develop and deliver a comprehensive treatment plan for our patients.
MD, Medical College of Pennsylvania (Drexel University School of Medicine) 1994
Internal Medicine, Temple University Hospital, Philadelphia, PA
Endocrine, Diabetes and Metabolism, Temple University Hospital, Philadelphia, PA
Honors and Awards
Best Doctors in America, 2005 - 2013;
Outstanding Faculty Consultant Faculty Educator Award, Temple University School of Medicine, 2008, 2009
- Fraga PD, Vojta C, Veloski C. A review of hormone replacement therapy for disease prevention. Hospital Physician. August 1999.
- Veloski CD. NCEP Guidelines (editorial comment). Medical Crossfire. February 2002.
- Veloski C. "Osteoporosis" in Women's Health in Clinical Practice, Clouse A, Sherif K, editors; Philadelphia: Humana Press, July 2007.
- Bonakdarpour A, Veloski C. "Disturbances of Endocrine Function" in Diagnostic Imaging and Pathology of Musculoslokeletal Diseases, Bonakdarpour A, editor.
- Veloski C, Siraj E. Update on thyroid nodules and thyroid cancer. Journal of Clinical Outcomes Management. September 2008.
- Tchong L, Veloski C, Siraj E. Update on hypothyroidism. Journal of Clinical Outcomes Management. May 2009.
- Barclay D, Veloski C. Cushing’s syndrome and Cushing’s disease. 5-Minute Medical Consult 2009.
- Veloski C, Brennan. Critical Care Endocrinology in Critical Care Study Guide, Criner G, Barnette R, D’Alonzo G, editors. Philadelphia, PA, Springer 2009. (in Press)
- Swe N, Rosenberg D, Veloski C, Marks A. An occult pheochromocytoma in a patient with neurofibromatosis 1 unmasked by hemodynamic crisis upon induction of anesthesia (Case Report). The Endocrine Society’s 89th Annual Meeting in Toronto, Canada, June 2007
- Veloski C, Pineyro M, Siraj, E. Abnormal 17-OHP Responsiveness in a patient with adrenocortical neoplasm (Case Report). AACE Annual Meeting in Seattle, Washington, April 2007.
- Gonzalez-Pantaleon AD,Veloski C, Siraj ES. Metastatic papillary thyroid cancer presenting as a parasellar mass (Case Report). AACE Annual Meeting, Orlando, Florida, May 2008.
- Tchong L,Veloski C, Siraj ES. Simultaneous presentation of prolactinoma and vestibular schwannoma. (Case Report). AACE Annual Meeting, Orlando, Florida, May 2008.
- Yarlagadda M, Veloski C, Siraj ES. Co-existence of retroperitoneal paraganglioma and glucocorticoid secreting adrenocortical adenoma. AACE Annual Meeting, Houston, Texas May 2009.
- Yarlagadda M, Veloski C. Toxic Nodule Masking Thyroid Hemiagenesis: A Case Report. ATA Annual Meeting, Palm Beach, Florida, September 2009.